Skip to content

Investigation of side effects of carvacrol in humans

The frst phase of clinical trial of of carvacrol to evaluate the safety and tolerability of the substance in humans

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
IRCT
Registry ID
IRCT2016080429191N1
Enrollment
40
Registered
2016-11-19
Start date
2016-09-22
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy volunteers. -

Interventions

Intervention 1: Carvacrol, Capsules cantain 30 mg carvacrol, three times per day for one month. Intervention 2: Carvacrol, Capsules cantain 47 mg carvacrol, three times per day for one month.
Treatment - Drugs
Carvacrol, Capsules cantain 30 mg carvacrol, three times per day for one month
Carvacrol, Capsules cantain 47 mg carvacrol, three times per day for one month

Sponsors

Vice chancellor for research, Mashhad University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 60 Years

Inclusion criteria

Inclusion criteria: Main conditions of entry to study: Physical and mental health; no history of serious illness; the age limit from 20 to 60 years; write informed consent Main condition of exclusion from study: cardiovascular diseases; brain and vascular disease; malignancy; chronic inflammatory diseases; autoimmune disorders; psychiatric disorders; metabolic diseases; endocrine disorders; other underlying diseases other than those mentioned; one tends to withdraw from the study; drug intolerance; drug use by participants during the study

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Biochemical factors. Timepoint: Before and one month after intervention. Method of measurement: Device analysis.;Hormonal factors. Timepoint: Before and one month after intervention. Method of measurement: Device analysiis.;Blood factors. Timepoint: Befor and one month after intervention. Method of measurement: Device analysis.

Secondary

MeasureTime frame
-. Timepoint: -. Method of measurement: -.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactVahideh Ghorani Sirjani

Mashhad University of Medical Sciences

Ghoranisv921@mums.ac.ir+98 51 3882 8888

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026